Milner

American Institutes for Research Welcomes New Fellows Focused on Equity in Education and Public Safety

Retrieved on: 
Wednesday, July 12, 2023
Milner, American Educational Research Association, Education, AERA, Research, Vanderbilt, Johns Hopkins University, AIR, STEM, Hopkins Center for the Arts, Knowledge, Growth, Data science, Management

Odis Johnson Jr., a professor of social policy and STEM equity at Johns Hopkins University and executive director of the Hopkins Center for Safe and Healthy Schools.

Key Points: 
  • Odis Johnson Jr., a professor of social policy and STEM equity at Johns Hopkins University and executive director of the Hopkins Center for Safe and Healthy Schools.
  • His work focuses on the intersections of social policy, data science and race; and
    H. Richard (Rich) Milner IV, a professor of education at Vanderbilt University’s Peabody College, immediate past President of the American Educational Research Association (AERA), and researcher and author on issues of urban education.
  • Milner and Dr. Johnson are prolific scholars who bring a wealth of knowledge in education, policing, the school-to-prison pipeline, and research methods,” said Rashawn Ray , AIR vice president and executive director of the AIR Equity Initiative.
  • “It is an honor to have them join AIR in our journey toward mitigating the harmful effects of segregation by race and place.”

Canada's Preeminent Neuropsychologist Dr. Brenda Milner is the Newest Inductee to Canada's Walk of Fame

Retrieved on: 
Wednesday, June 21, 2023
Psychology, Milner, Neuropsychology, Sport, The arts, Social justice, Culture, Ageing, NHL, CTV, Innovation, Research, Brain, Celebration, Coordinated Specialty Care, Humanitarianism, Metro Toronto Convention Centre, 2001 in the sport of athletics, Supreme court, Human rights, McGill University, Federal Ministry of Science, Technology and Innovation, Sensation, Arts and Entertainment, Neurology, Television, Medical device, Lists of College Football Hall of Fame inductees, Science, Fame

Professor Emerita at McGill University, she revolutionized the field of neuropsychology, combining neurology and psychology, and is considered one of the most important neuroscientists of the twentieth century.

Key Points: 
  • Professor Emerita at McGill University, she revolutionized the field of neuropsychology, combining neurology and psychology, and is considered one of the most important neuroscientists of the twentieth century.
  • "It means a lot to receive this honour from my adopted country and to be inducted into Canada's Walk of Fame.
  • I'm feeling lucky, and I'm grateful," Dr. Brenda Milner, 2023 Canada's Walk of Fame Inductee.
  • Dr. Milner did that and we can deeply connect with her approach and breakthrough findings."

Atria Wealth Solutions Recruits $1.1 Billion Wealth Management Team to Cadaret Grant from Signature Bank

Retrieved on: 
Wednesday, May 31, 2023
Milner, Partnership, AIP, Senior, Greg Cadaret, Retirement, Signature Bank, Flagstar Bank, Management, Atria

NEW YORK, May 31, 2023 /PRNewswire/ -- Atria Wealth Solutions, Inc. (Atria), a multi-channel wealth management solutions holding company, announced the recruitment of Edwin Milner, Laura Palacios and Jason Kurz from Flagstar Bank (formerly Signature Bank) to Atria subsidiary Cadaret Grant. Managing nearly $1.1 billion in total client assets, they will be an independent wealth management team associated with Cadaret Grant's largest branch – American Investment Planners (AIP), based in Jericho, New York. Milner, Palacios and Kurz provide comprehensive financial planning, retirement and private wealth management services to high-net-worth individuals, businesses and foundations.

Key Points: 
  • Former Signature Bank team joins one of Atria's subsidiaries' largest branches, American Investment Planners, to continue growth momentum
    NEW YORK, May 31, 2023 /PRNewswire/ -- Atria Wealth Solutions, Inc. (Atria), a multi-channel wealth management solutions holding company, announced the recruitment of Edwin Milner, Laura Palacios and Jason Kurz from Flagstar Bank (formerly Signature Bank) to Atria subsidiary Cadaret Grant.
  • Managing nearly $1.1 billion in total client assets, they will be an independent wealth management team associated with Cadaret Grant's largest branch – American Investment Planners (AIP), based in Jericho, New York.
  • Milner, Palacios and Kurz provide comprehensive financial planning, retirement and private wealth management services to high-net-worth individuals, businesses and foundations.
  • This is about creating a long-term relationship that empowers them to be their best and deliver an elite wealth management experience for their clients.

Collegiate Entrepreneurs' Organization partners with Amazon to design the new Amazon Small Business Academy

Retrieved on: 
Tuesday, March 21, 2023
University of Tampa, Milner, Small business, Indiana University, Commercialization, University, Marketing, Lower Rio Grande Valley, Curriculum, Behavior informatics, California State University, Hertz, Business, UTRGV, Woman, Innovation, Harris–Stowe State University, Multimedia, Wilson, ASBA, Student, Journal, Sam Houston State University, Rowan University, School, Jackson State University, Small Business Administration, SBA, Journal of Small Business Management, Sam Houston, Software, Online shopping, Management, Entrepreneurship, Amazon

The tracks address both the tactical fundamentals, as well as the skills, that small business owners need to build self-reliance, confidence and perseverance.

Key Points: 
  • The tracks address both the tactical fundamentals, as well as the skills, that small business owners need to build self-reliance, confidence and perseverance.
  • The program is free, open to any small business owner or entrepreneur and can be accessed at smallbusiness.amazon .
  • "Small business owners who take advantage of this academy can use these tools to think more entrepreneurial, and that directly services the mission of CEO."
  • From its inception in 1984, the organization has grown to approximately 16,500 members, representing nearly 250 college- and university-based chapters.

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Retrieved on: 
Friday, December 9, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Therapy, Baozou Big News Events, M. B, Exocrine gland, Selenium disulfide, Military medicine, Veteran, Diagnosis, Visual Science, Corneal ulcers in animals, Patient, Duane syndrome, Classification, Milner, MGS, OIS, Total, M. A, Drug development, Meibomian gland, News, MGD, European Ophthalmic Pathology Society, All rights reserved, Adverse Events, Luchs, Safety, Investigative Ophthalmology & Visual Science, Systematic review, Contact lens, AES, Prevalence, Pharmaceutical industry, Telescopic sight, Medical device, OSDI, Ophthalmology, Azura, Amit Majmudar

It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.

Key Points: 
  • It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
  • The results from Azuras Phase 2b study of AZR-MD-001 0.5% in MGD were presented during the Spotlight on Dry Eye session at OIS XII.
  • The Phase 2b trial was a multi-center, double-masked, vehicle-controlled, parallel group study that evaluated the safety and efficacy of AZR-MD-001 in 245 patients with MGD.
  • Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

Retrieved on: 
Monday, November 21, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, M. B, Duane syndrome, Selenium disulfide, Contact lens, Luchs, Exocrine gland, M. A, Drug development, Corneal ulcers in animals, Conference, Classification, Safety, Piper Sandler Companies, Therapy, Meibomian gland, Milner, European Ophthalmic Pathology Society, MGD, Diagnosis, Patient, Medical device, Telescopic sight, Pharmaceutical industry, Ophthalmology, Amit Majmudar, Azura

The Azura management team will also be available for 1X1 investor meetings.

Key Points: 
  • The Azura management team will also be available for 1X1 investor meetings.
  • AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.
  • Azura expects to initiate a second pivotal multi-center clinical trial of AZR-MD-001 0.5% in 2023.
  • Azura Ophthalmics is utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions.

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Total, Medical director, M. A, Irritation, Exocrine gland, MGS, Safety, Investigative Ophthalmology & Visual Science, Meibomian gland, European Ophthalmic Pathology Society, Veteran, MGD, AES, LASIK, United, Drug development, VAS, All rights reserved, Eyelid, Physician, Pain, Diagnosis, Patient, Duane syndrome, Prevalence, Selenium disulfide, Luchs, Corneal ulcers in animals, Classification, Gland, Military medicine, Therapy, Milner, SPEED, Business, M. B, Systematic review, Adverse Events, Contact lens, Warrenville, Pharmaceutical industry, Medical imaging, Telescopic sight, Medical device, OSDI, Ophthalmology, Amit Majmudar, Azura

Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).
  • We are thrilled to build upon these positive results by advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
  • I look forward to collaborating with the Azura team and my fellow scientific advisory board members to advance AZR-MD-001.
  • Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents

Retrieved on: 
Wednesday, October 19, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, LinkedIn, Meibomian gland, Disease, Therapy, Duane syndrome, Inflammation, Diagnosis, Ophthalmic drug administration, Corneal ulcers in animals, Patient, Exocrine gland, Drug development, Luchs, Keratolytic, Twitter, Â, Severe cognitive impairment, M. A, DED, M. B, MGD, CLD, IP, Patent, Safety, Blepharitis, Classification, Milner, Selenium disulfide, Pharmaceutical industry, Vaccine, Telescopic sight, Medical device, Amit Majmudar, Demodex, Ophthalmology, Azura

The expansion of Azuras IP portfolio to 12 U.S. and European patents, and at least 104 patents and patent applications worldwide, validates our novel approach to harness and develop first-in-class treatments that have the potential to completely change the treatment and outcomes of lid margin and ocular surface diseases, said Marc Gleeson, Chief Executive Officer of Azura Ophthalmics.

Key Points: 
  • The expansion of Azuras IP portfolio to 12 U.S. and European patents, and at least 104 patents and patent applications worldwide, validates our novel approach to harness and develop first-in-class treatments that have the potential to completely change the treatment and outcomes of lid margin and ocular surface diseases, said Marc Gleeson, Chief Executive Officer of Azura Ophthalmics.
  • Azura expects to report Phase 2b three-month topline data in the fourth quarter of 2022.
  • Azura Ophthalmics is utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions.
  • Our internally discovered pipeline of new chemical entities allows us to develop a portfolio of first-in-class ophthalmic therapeutics for significant unmet needs.

Freed-Hardeman Alumni, Friends and Students to Celebrate Homecoming Nov. 11-13

Retrieved on: 
Wednesday, October 5, 2022
University of South Florida Athletic Hall of Fame, Social club, Veteran, Oregon Sports Hall of Fame, Kigali Arena, Education, NAIA Women's Basketball Championships, Parent, Distinguished Service Award, A Lion Walks Among Us, The Story of Us, Musical, Partnership, Student, Matilda the Musical, Freed–Hardeman University, Strontium aluminate, Penn State Lady Lions basketball, FHC, Old Main (Pennsylvania State University), Friends, List of Old Main buildings, LSU, Hall, Grandparent, Jesus, FHU, Male, Sport, Homecoming, Man, London Lions (basketball), Milner, World Golf Village, Women's basketball, Nightclub, Fireworks, Entertainment, Tutoring, Old Chapel Hall

HENDERSON, Tenn., Oct. 4, 2022 /PRNewswire-PRWeb/ -- Alumni, parents and friends will celebrate Freed-Hardeman University Homecoming 2022: The Story of Us Friday, Nov. 11, through Sunday, Nov. 13, 2022.

Key Points: 
  • HENDERSON, Tenn., Oct. 4, 2022 /PRNewswire-PRWeb/ -- Alumni, parents and friends will celebrate Freed-Hardeman University Homecoming 2022: The Story of Us Friday, Nov. 11, through Sunday, Nov. 13, 2022.
  • Special programs are planned for homecoming week chapels, held at 10:30 a.m. Monday, Nov. 7, through Friday, Nov. 11.
  • At this annual event, alumni spend time with students to network and share career advice, wisdom, expertise and experience.
  • The FHU family will celebrate the renovation of Paul Gray men's dorm with a ribbon cutting at 2 p.m. Friday, Nov. 11.

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Retrieved on: 
Wednesday, September 28, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, Science, Therapy, Safety, Trial of the century, Twitter, FDA, Food, OSDI, AZR, Duane syndrome, IND, LinkedIn, Population, MGS, CLD, Exocrine gland, DED, Selenium disulfide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, CEO, M. A, Corneal ulcers in animals, Severe cognitive impairment, M. B, Diagnosis, Meibomian gland, Drug development, Investigational New Drug, Milner, Classification, Luchs, Ophthalmic drug administration, MGD, Pharmaceutical industry, Telescopic sight, Medical device, Azura, Ophthalmology, Amit Majmudar

Meibomian Gland Dysfunction is the leading cause of Dry Eye Disease and Contact Lens Discomfort impacting millions of people in the U.S. alone, said Marc Gleeson, CEO of Azura Ophthalmics.

Key Points: 
  • Meibomian Gland Dysfunction is the leading cause of Dry Eye Disease and Contact Lens Discomfort impacting millions of people in the U.S. alone, said Marc Gleeson, CEO of Azura Ophthalmics.
  • Azura is currently conducting a multi-center, double-masked, vehicle-controlled Phase 2b study that will evaluate the safety and efficacy of AZR-MD-001 in patients with MGD.
  • The ongoing study builds upon previous findings from a successful Phase 2a clinical trial evaluating AZR-MD-001 in the same patient population.
  • Meibomian Gland Dysfunction (MGD) is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum.